Reuters
Published Apr 04, 2022 03:00PM ET
Updated Apr 04, 2022 06:16PM ET
(Reuters) -The U.S. national public health agency said on Monday the BA.2 sub-variant of Omicron was estimated to account for nearly three of every four coronavirus variants in the country.
Overall COVID-19 cases in the United States have dropped sharply after hitting record levels in January, but a resurgence in cases in parts of Asia and Europe has raised concerns that another wave could follow in the United States. The country's health experts, however, believe it is unlikely.
The seven-day moving average of U.S. COVID cases was 26,106 as of April 1, marginally lower than 26,309 from a week earlier, as per data from the U.S. Centers for Disease Control and Prevention (CDC).
The highly transmissible BA.2 sub-variant makes up 72.2% of the COVID variants in the United States, as of April 2, up from nearly 57.3% in the preceding week, according to CDC estimates.
BA.2 now makes up about 86% of all sequenced cases globally, according to the World Health Organization. It is known to be more transmissible than the BA.1 and BA.1.1 Omicron sub-variants, however, the evidence so far suggests that it is no more likely to cause severe disease.
Amid waning immunity and risks posed by the Omicron variants, U.S. health regulators authorized a second booster dose of Pfizer/BioNtech and Moderna (NASDAQ:MRNA)'s vaccine last week, for people aged 50 and above, as well as for younger people with compromised immune systems.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.